COVID-19 Vaccines 2023
COVID-19 Vaccines 2023
Innovative vaccine platforms such as DNA, mRNA, virus-like particles, viral vector, recombinant protein, and live attenuated and inactivated virus approaches have developed COVID-19 vaccines.
On August 23, 2021, the U.S. Food and Drug Administration (FDA) Authorized the Approved various versions of the Pfizer-BioNTech mRNA Comirnaty vaccine. It also has Approved the SpikeVax from Moderna, Inc., and the Jcovden vaccine was Authorized as of June 2022. In addition, on July 13, 2022, the FDA authorized Novavax's protein-based COVID-19 vaccine.
The FDA published an article on January 13, 2023: Identify Preliminary COVID-19 Vaccine Safety Signal for Persons 65 Years and Older. And on January 26, 2023, the FDA's Vaccines and Related Biological Products Advisory Committee is review this Briefing Document.
The UK's Joint Committee on Vaccination and Immunisation published a statement regarding 2023 COVID-19 vaccination program recommendations for 2023 and a related Independent Report analysis on January 25, 2023. Data reported on January 30, 2023, indicates 13.1 billion doses of COVID-19 vaccines have been administered glabally, with 89% of health workers and 81% of older adults (over 60 years) having completed the primary series.
The European Medicines Agency (EMA) has Authorized COVID-19 vaccines as of January 2023. Furthermore, the World Health Organization (WHO) has Listed various COVID-19 vaccines. In addition, on December 14, 2022, the WHO published a standard analytic report produced by the COVID-19 Vaccine Delivery Partnership.
COVID-19 Vaccine Studies 2023
January 27, 2023 - The Joint Committee on Vaccination and Immunisation published conditions for the 2023 COVID-19 vaccination program in the UK.
January 20, 2023 - The Lancet preprint published - Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNtech) in Aotearoa New Zealand. Interpretation: Although rare, a statistically significant association between BNT162b2 vaccination and myo/pericarditis and acute kidney injury (AKI) was observed. While the association between BNT162b2 and myo/pericarditis has been confirmed internationally, further research is required to understand the association of AKI.
January 12, 2023 - The peer-review journal Frontiers in Immunology published Original Research: mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine.
January 9, 2023 - Researchers from the Korea Disease Control and Prevention Agency published a study in The JAMA Network Pediatrics involving children aged 5 to 11 years, estimating the vaccine effectiveness of two doses of the monovalent Pfizer/BioNTech COVID-19 vaccine against Omicron infection to be up to 58% effective with 100% protection against critical illness for up to three months.
January 5, 2023 - Springer published: Changes of ECG parameters after BNT162b2 vaccine in the senior high school students. Conclusion: Cardiac symptoms are common after the second dose of the BNT162b2 vaccine, but the incidences of significant arrhythmias and myocarditis are only 0.1%. The serial ECG screening method has high sensitivity and specificity for significant cardiac adverse effects, but the cost effect needs further discussion.
January 5, 2023 - The Lancet published a Correspondence: Stability of hybrid versus vaccine immunity against BA.5 infection over eight months. This study shows hybrid immunity following infection with Omicron BA.1 or BA.2, compared with vaccine-only immunity, substantially increases protection against BA.5 reinfection for up to 8 months.
January 3, 2023 - Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in U.S. veterans. The 16-week risks of COVID-19 outcomes were low after a third dose of mRNA-1273 or BNT162b2, although risks were lower with mRNA-1273 than with BNT162b2, particularly for documented infection.
January 2, 2023 - The journal Nature Medicine published an article: Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. These findings suggest that, although vaccinated and/or previously infected individuals remain highly infectious upon SARS-CoV-2 infection in this prison setting, their infectiousness is reduced compared to individuals without any history of vaccination or infection. This study underscores the benefit of vaccination to reduce, but not eliminate, transmission.
December 19, 2022 - Among 51,011 working-aged Cleveland Clinic employees, the bivalent COVID-19 vaccine booster was 30% effective in preventing infection.
Additional vaccine news is published at PrecisionVaccinations.com/vaccines.
COVID-19 Antivirals 2023
The U.S. FDA and EMA have Approved and Authorized various antivirals (oral and IV) to treat COVID-19 infections.
SARS-CoV-2 9 Monoclonal Antibody 2023
The U.S. FDA and the EMA have authorized monoclonal antibody therapies during the COVID-19 pandemic.